Physician profile
Eric W Byrd
NPI 1184699621
$4,316.57
in general payments reported to CMS, 2019-2025
26 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $694 · 2021: $1,017 · 2022: $658 · 2023: $510 · 2024: $470 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $773.65 | 2019-2024 | |
| Amgen INC. | $496.28 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals Lp | $455.16 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $265.41 | 2020-2022 | |
| Glaxosmithkline, LLC. | $255.08 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $249.92 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $226.03 | 2022-2025 | Qulipta, Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $223.57 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $219.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.73 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $181.40 | 2019-2025 | Eliquis |
| Amarin Pharma, INC. | $149.76 | 2019-2022 | |
| Novo Nordisk INC | $97.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $95.39 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $74.30 | 2023-2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $63.15 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $50.01 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.57 | 2024-2025 | Xifaxan |
| Radius Health, INC. | $37.85 | 2020-2021 | |
| Medtronic, INC. | $25.93 | 2024 | Intellis Adaptivestim |
| Globus Medical, INC. | $24.13 | 2025 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $23.12 | 2021 | |
| Eisai INC. | $19.75 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.58 | 2025 | Gvoke Hypopen |
| Lucid Diagnostics INC. | $17.13 | 2025 | |
| Esperion Therapeutics, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.